Background Equitable representation of racially and ethnically diverse subpopulations in
clinical trials continues to be a problem, and trial participants do not always reflect the …

Clinical trial participant populations fail to adequately represent target populations that drugs
are intended to serve. Improving racial and ethnic diversity of clinical trial participants is …

Introduction In recent years, there has been increasing awareness of the lack of diversity
among clinical trial participants. Equitable representation is key when testing novel …

The representation of racial and ethnic minority populations in clinical trials continues to be
a challenge despite mandates, good intentions, and concerted efforts by funding agencies …

Introduction Engaging communities in research planning and implementation can enhance
recruitment and retention (R&R) of racial and ethnic groups historically excluded and …

Women and people from most racial and ethnic groups in the United States have historically
been under‐represented in clinical trials of investigational medical products. Inadequate …

Background The lack of racial and ethnic diversity in clinical trials leads to skewed findings,
limited generalizability, inequitable health outcomes for people of color, and insufficient …

Underrepresentation among clinical trial participants contributes to evident health disparities
and increasing diversity in clinical research is mutually beneficial to patients, providers, and …

Current clinical research does not reflect the diversity of patient populations, despite
continued recommendations to increase enrollment of under‐represented racial and ethnic …

Background Improving diversity in clinical trials is essential in order to produce
generalizable results. Although the importance of representation has become increasingly …